Stereotactic Intracranial Biopsy Outcomes: Insights from a 15-Year Institutional Review - Scorecard - MDSpire

Stereotactic Intracranial Biopsy Outcomes: Insights from a 15-Year Institutional Review

  • By

  • Vratko Himic

  • Sebastian Vargas-George

  • Maxon V. Knott

  • Vaidya Govindarajan

  • Seth S. Tigchelaar

  • Tyler M. Cardinal

  • Adham M. Khalafallah

  • Victor M. Lu

  • Hatun Mine Sahin

  • Arnold Lang

  • Zachary C. Gersey

  • Daniel M. Aaronson

  • Ricardo J. Komotar

  • Ashish H. Shah

  • Michael E. Ivan

  • April 21, 2026

  • 0 min

Share

Clinical Scorecard: Stereotactic Intracranial Biopsy Outcomes: Insights from a 15-Year Institutional Review

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with intracranial lesions, particularly those with small or indeterminate lesions, aged 18 and above.
Care Setting

Key Highlights

  • Reporting of negative biopsy outcomes is essential for improving clinical protocols.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Follow-up strategies should be standardized to improve patient outcomes, with specific timeframes for follow-up assessments.

      Risks

        Patient & Prescribing Data

        Patients undergoing stereotactic biopsy for intracranial lesions from 2011 to 2024, with a focus on outcomes within 6 months post-biopsy.

        Clinical Best Practices

        • Ensure meticulous planning and technique to minimize non-diagnostic outcomes.
        • Utilize advanced imaging and stereotactic systems to enhance biopsy accuracy.
        • Document and analyze non-diagnostic cases to improve future protocols.
        • Educate patients on the risks and potential outcomes of the biopsy procedure.

        References

        Original Source(s)

        Related Content